Chlorproguanil/dapsone/artesunate: Difference between revisions
Content deleted Content added
No edit summary |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{{ |
{{technical}} |
||
{{importance}} |
{{importance}} |
||
{{tense}} |
{{tense}} |
||
Revision as of 18:15, 12 April 2008
 | This article may be too technical for most readers to understand. |
| This article may use tenses incorrectly. |
 | The examples and perspective in this article may not represent a worldwide view of the subject. |
Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine (Coartem®) and against chlorproguanil-dapsone Lapdap™. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[1]
References
- ^ Das P (2006). "Promising anti-malarial enters phase II studies". Lancet Infect Dis. 6 (9): 551.
External links
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |